GURU.Markets stock price, segment price, and overall market index valuation
The company's share price DiaMedica Therapeutics
DiaMedica, a biotech company focused on treating kidney disease and stroke, shares reflect the progress of its clinical programs. Their price is highly volatile, depending on research results and investor confidence in the potential of its drugs.
Share prices of companies in the market segment - Pharma kidney
DiaMedica Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of neurological and renal diseases, particularly ischemic stroke and kidney disease. We have classified it in the "Pharma Kidney" segment. The chart below reflects the dynamics in this complex area of pharmaceuticals, where the need for new treatments is high.
Broad Market Index - GURU.Markets
DiaMedica Therapeutics is a biopharmaceutical company developing drugs for the treatment of ischemic stroke and chronic kidney disease. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how DiaMedica shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
DMAC - Daily change in the company's share price DiaMedica Therapeutics
For DiaMedica Therapeutics, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Pharma kidney
DiaMedica Therapeutics Inc. is a biotech company. This chart highlights the sector's extreme volatility. Comparison with DMAC, which focuses on kidney disease treatments, helps to assess it as a high-risk, data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
DiaMedica is a biopharmaceutical company developing drugs to treat kidney diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing DiaMedica's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization DiaMedica Therapeutics
DiaMedica Therapeutics' year-to-date performance is a story of developing drugs for the treatment of stroke and kidney disease. Its 12-month market cap depends entirely on clinical trial results. Any positive data could dramatically change its valuation, as it targets huge markets with unmet medical needs.
Annual dynamics of market capitalization of the market segment - Pharma kidney
DiaMedica Therapeutics Inc. is a clinical-stage biotech developing drugs for the treatment of kidney disease and stroke. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in these areas.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
DiaMedica is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization DiaMedica Therapeutics
The performance of DiaMedica, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its drug for the treatment of kidney disease and stroke, the success of which determines its future.
Monthly dynamics of market capitalization of the market segment - Pharma kidney
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing new treatments for chronic kidney disease and stroke. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it's possible to assess the progress of its drug, which aims to restore normal vascular function, in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
DiaMedica is a biopharmaceutical company focused on treating kidney disease and stroke. Its shares are buoyed by anticipation of clinical trial results. The chart shows that the company's monthly price fluctuations are unrelated to overall market trends, but rather reflect specific scientific news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization DiaMedica Therapeutics
DiaMedica Therapeutics, a biopharmaceutical company focused on treating kidney diseases, is in a high-risk sector. Its weekly stock price is almost entirely dependent on news about clinical trials and regulatory decisions, rather than on overall market trends, resulting in high volatility.
Weekly dynamics of market capitalization of the market segment - Pharma kidney
Biotech companies working in kidney disease treatment, like DiaMedica, are riding the wave of industry-wide news. The chart below illustrates this industry sentiment. It allows one to assess how promising the market perceives DiaMedica's approach compared to developments by other companies solving similar medical problems.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
DiaMedica Therapeutics is a clinical-stage biotech focused on treating kidney diseases. Its stock moves not with the market, but on research news. This chart shows how trial successes and failures cause fluctuations that defy overall trends.
Market capitalization of the company, segment and market as a whole
DMAC - Market capitalization of the company DiaMedica Therapeutics
DiaMedica Therapeutics' market capitalization represents the financial promise of new treatments for kidney disease and stroke. Its performance hinges entirely on the clinical trial results of its recombinant protein. Its volatility and small size indicate high risk and potentially enormous reward if its developments are successful.
DMAC - Share of the company's market capitalization DiaMedica Therapeutics within the market segment - Pharma kidney
DiaMedica Therapeutics is a biotech company focused on treating kidney diseases and neurological disorders. As a highly specialized player, its share of the pharmaceutical sector's market capitalization is small. However, for investors, this dynamic metric demonstrates the market's confidence in the success of its clinical trials and the potential of its drugs.
Market capitalization of the market segment - Pharma kidney
This chart shows the total market capitalization of the pharmaceutical sector specializing in kidney diseases. It's a multibillion-dollar market, reflecting the scale of the problem. For DiaMedica Therapeutics, a small company developing targeted drugs, the rising value of this chart indicates the increasing potential reward if its clinical trials are successful.
Market capitalization of all companies included in a broad market index - GURU.Markets
DiaMedica Therapeutics develops drugs to treat chronic kidney disease. Its market capitalization, relative to the overall market, represents a financial expression of hope for millions of patients. It represents the stake investors are putting into the fight against one of the most common diseases.
Book value capitalization of the company, segment and market as a whole
DMAC - Book value capitalization of the company DiaMedica Therapeutics
DiaMedica Therapeutics is a biotech company focused on treating kidney disease and stroke. Its book value represents its financial cushion, consisting of cash allocated for costly clinical trials. How has this vital cash cushion changed? The chart below shows the dynamics.
DMAC - Share of the company's book capitalization DiaMedica Therapeutics within the market segment - Pharma kidney
DiaMedica Therapeutics develops drugs for the treatment of kidney diseases, and its scientific potential is supported by its facilities. These include modern laboratories equipped for preclinical and clinical trials. The chart shows the company's share of the physical R&D infrastructure in this niche pharmaceutical segment.
Market segment balance sheet capitalization - Pharma kidney
DiaMedica, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
DiaMedica's balance sheet is not its production capacity, but its intellectual property: patents and clinical trial data for drugs for kidney disease and stroke. The company's assets are capitalized science. The chart shows how these intangible assets are valued in the biotech sector.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - DiaMedica Therapeutics
DiaMedica's balance sheet is capitalized R&D costs. Its entire market value is a premium on hope, a bet investors make that its kidney disease drug will successfully complete trials. The chart is a visualization of these hopes in anticipation of key company news.
Market to book capitalization ratio in a market segment - Pharma kidney
DiaMedica is a clinical-stage biotech focused on treating kidney disease. Its market capitalization on this chart represents investors' hopes for successful clinical trials. This metric demonstrates the vast gap between current assets (primarily cash) and potential future value.
Market to book capitalization ratio for the market as a whole
DiaMedica Therapeutics is a biotech company developing drugs to treat kidney diseases. Its market value is based solely on the expectation of clinical trial success. This chart clearly demonstrates the extreme discrepancy between book value and market valuation for science-based startups.
Debts of the company, segment and market as a whole
DMAC - Company debts DiaMedica Therapeutics
DiaMedica Therapeutics, a clinical-stage biopharmaceutical company, uses equity to fund research into its drugs for kidney disease and stroke. Debt instruments at this stage can be risky, but they allow the trials to advance. This chart shows how the company manages its resources on the long road to potential drug approval.
Market segment debts - Pharma kidney
DiaMedica Therapeutics is a clinical-stage biotech company whose value lies in the potential of its future drugs. Financing at this stage is almost always through equity, as debt is too risky. This chart clearly demonstrates the typical strategy for the sector to survive and grow without significant debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio DiaMedica Therapeutics
DiaMedica is a biopharmaceutical company, and its financial strategy is closely tied to clinical trials. This chart shows the debt-to-equity ratio, which is an indicator of investor confidence in a potential drug. Increasing debt may signal progress toward the final stages of research, but it also indicates an increased risk of failure.
Market segment debt to market segment book capitalization - Pharma kidney
DiaMedica Therapeutics develops drugs to treat kidney diseases and neurological disorders. Biopharmaceutical research is a long and expensive process. This chart illustrates how the industry as a whole uses debt financing to conduct clinical trials, helping to evaluate DiaMedica's financial strategy against its competitors.
Debt to book value of all companies in the market
DiaMedica Therapeutics, focused on treating kidney disease, is undergoing a lengthy clinical trial—the most capital-intensive stage in biotech. This chart compares the market's total debt to its book value. Analyzing DiaMedica's debt position in this light demonstrates how typical its financial strategy is for the industry as it moves toward commercialization.
P/E of the company, segment and market as a whole
P/E - DiaMedica Therapeutics
DiaMedica Therapeutics is a biopharmaceutical company developing drugs for the treatment of chronic kidney diseases and neurological disorders. This chart shows the price-to-earnings ratio, but for a clinical-stage company, it's not the key metric. Investors' valuation here is based on research results and the potential of its drugs to transform treatment approaches.
P/E of the market segment - Pharma kidney
DiaMedica is a clinical-stage biotech company. This chart shows the average valuation for the pharmaceutical sector. For DiaMedica, it serves as a contrast: while the industry is generally valued based on revenue, DiaMedica's valuation is entirely dependent on clinical trial expectations, not current financial performance.
P/E of the market as a whole
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing innovative treatments for chronic kidney disease and acute ischemic stroke. This chart reflects the overall risk appetite of investors in the biotech sector. It helps understand whether DMAC's valuation is based on confidence in the potential of its drugs or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company DiaMedica Therapeutics
DiaMedica Therapeutics develops drugs for the treatment of kidney diseases and neurological disorders. The company's future profitability depends on successful clinical trial results and subsequent approval of its drugs. This chart illustrates investor and analyst expectations regarding the scientific and commercial potential of its developments.
%20P%2FE%20DiaMedica%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-DiaMedica-Therapeutics&v=1772640436677 "Chart of the company's future (projected) P/E DiaMedica Therapeutics")
Future (projected) P/E of the market segment - Pharma kidney
DiaMedica Therapeutics is focused on developing drugs for chronic kidney disease, where there is a significant unmet need. This data reflects analysts' collective expectations for the success of its clinical trials compared to other biotech companies. It serves as a barometer of expectations for a breakthrough in the treatment of this complex disease.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-kidney&v=1772640436684 "Future (projected) P/E graph of the market segment - Pharma kidney")
Future (projected) P/E of the market as a whole
DiaMedica Therapeutics, which develops drugs to treat kidney disease, is an early-stage biotech. This sentiment chart shows the market's willingness to fund long-term, risky research. DiaMedica's success depends not only on its science but also on access to capital during periods of optimism.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772640436705 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit DiaMedica Therapeutics
DiaMedica Therapeutics is a biotech company focused on developing drugs for the treatment of kidney diseases and neurological disorders. This chart illustrates the financial costs of conducting clinical trials. It doesn't represent current profits, but rather investments in research that, if successful, could lead to the development of a life-saving drug.
Profit of companies in the market segment - Pharma kidney
DiaMedica Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of kidney diseases and neurological disorders. Being in the clinical stage, its current financial performance reflects research expenses. However, the potential success of its drugs could dramatically change the profitability picture, demonstrating the biotech model: heavy investment for future breakthroughs.
Overall market profit
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company developing treatments for acute ischemic stroke and chronic kidney disease. These are conditions with a significant unmet medical need. The company's potential success could bring significant benefits to patients and reflects its ongoing pursuit of breakthrough solutions in medicine.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company DiaMedica Therapeutics
DiaMedica Therapeutics is a clinical-stage biotech company focused on treating kidney diseases and neurological disorders. This chart shows analysts' speculative expectations. Future profits depend entirely on the success of their drug candidates' clinical trials, and any news about their progress could dramatically change their forecast.
%20profit%20of%20the%20company%20DiaMedica%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-DiaMedica-Therapeutics&v=1772640436775 "Graph of future (projected) profit of the company DiaMedica Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma kidney
DiaMedica Therapeutics is focused on developing drugs to treat chronic kidney disease and stroke—areas with significant unmet needs. This chart shows overall revenue projections for the pharmaceutical industry. It provides context for assessing the potential of DiaMedica's drugs, the success of which could radically change its position in the industry.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-kidney&v=1772640436889 "Graph of future (predicted) profits of companies in a market segment - Pharma kidney")
Future (predicted) profit of the market as a whole
DiaMedica Therapeutics is a biopharmaceutical company focused on treating kidney diseases and neurological disorders. While demand for its future drugs will be determined by specific indications, funding for clinical trials is highly dependent on market sentiment. A positive economic environment, reflected in the chart, facilitates capital raising.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772640436952 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - DiaMedica Therapeutics
DiaMedica Therapeutics is a biopharmaceutical company developing treatments for kidney diseases and neurological disorders. Being in the clinical stage, it may not generate significant revenue. This chart shows how investors evaluate its potential relative to its market capitalization, betting on the future success of clinical trials.
P/S market segment - Pharma kidney
DiaMedica Therapeutics is a biopharmaceutical company focused on developing treatments for chronic kidney disease and neurological disorders. This chart shows the average revenue estimate in the pharmaceutical industry. It helps understand whether the market believes in the company's clinical development potential as strongly as the industry average.
P/S of the market as a whole
DiaMedica Therapeutics is a biopharmaceutical company focused on developing treatments for chronic kidney disease and stroke. Its revenue potential depends on the success of clinical trials and regulatory approvals. This chart shows how investors value companies based on current revenue, providing context for biotech valuations.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company DiaMedica Therapeutics
DiaMedica Therapeutics is a clinical-stage biotech company focused on treating kidney diseases. This chart shows investor estimates of potential future revenues from its drug candidates. This reflects the market's confidence in the success of clinical trials and the subsequent commercialization of breakthrough treatments.
%20P%2FS%20DiaMedica%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-DiaMedica-Therapeutics&v=1772640437123 "The graph of the company's future (projected) P/S DiaMedica Therapeutics")
Future (projected) P/S of the market segment - Pharma kidney
DiaMedica Therapeutics is a biopharmaceutical company developing treatments for chronic kidney disease and stroke. This chart compares market expectations for its future revenue with those of other companies in the sector. The valuation reflects investors' speculative expectations for successful clinical trial results for its key drug candidate.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-kidney&v=1772640437138 "Future (projected) P/S market segment graph - Pharma kidney")
Future (projected) P/S of the market as a whole
DiaMedica Therapeutics is a biotech company whose value is derived from the success of clinical trials of new drugs for kidney disease. While this chart reflects revenue expectations for established businesses, DiaMedica's key drivers are scientific data and regulatory approvals, not general economic cycles.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772640437173 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales DiaMedica Therapeutics
This chart illustrates the revenue of DiaMedica Therapeutics, a clinical-stage biopharmaceutical company. Its revenue is typically minimal or nonexistent, as the company has not yet brought its drugs to market. Any income may come from licensing agreements or grants. The chart essentially reflects the stage at which the company is fully focused on research and development.
Sales of companies in the market segment - Pharma kidney
DiaMedica Therapeutics is a biopharmaceutical company focused on developing new treatments for chronic kidney disease and stroke. Its success depends on the results of clinical trials. This chart shows revenue in the kidney pharmaceutical sector. It illustrates the overall market size and the need for new drugs that DiaMedica's innovative therapies address.
Overall market sales
DiaMedica Therapeutics focuses on developing drugs to treat kidney diseases and neurological disorders. Demand for its drug candidates is driven by medical needs. However, the overall economic situation, reflected in this chart, impacts the healthcare system and its ability to fund innovative therapies once they are approved by regulators.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company DiaMedica Therapeutics
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on the treatment of kidney diseases and neurological disorders. This revenue projection chart is speculative, as the company does not yet have commercial products. Its dynamics reflect analyst expectations for successful clinical trial results and potential future market launches.
%20sales%20of%20the%20company%20DiaMedica%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-DiaMedica-Therapeutics&v=1772640437270 "Schedule of future (projected) sales of the company DiaMedica Therapeutics")
Future (projected) sales of companies in the market segment - Pharma kidney
DiaMedica Therapeutics is a biopharmaceutical company focused on developing treatments for chronic kidney diseases and neurological disorders with unmet medical needs. This chart shows projected revenue for the kidney pharmaceutical sector, reflecting growth expectations for this important market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-kidney&v=1772640437300 "Schedule of future (projected) sales of companies in the market segment - Pharma kidney")
Future (projected) sales of the market as a whole
DiaMedica Therapeutics develops drugs to treat kidney diseases and neurological disorders. While demand for its future products will be determined by medical indications, overall economic stability is important. It ensures sustainable funding for healthcare systems, which ensure access to innovative treatments for patients.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772640437333 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality DiaMedica Therapeutics
DiaMedica Therapeutics is a clinical-stage biotech focused on treating kidney diseases and neurological disorders. This chart captures the harsh reality of R&D: significant research costs with no revenue. It's a visualization of investing in the future, where the success of a single drug can recoup all costs many times over.
Market segment marginality - Pharma kidney
DiaMedica Therapeutics is a biopharmaceutical company focused on treating neurological and renal diseases. This chart compares its operating efficiency with that of other companies in clinical development. Above-average profitability in this segment is often due not to sales but to effective management of R&D costs.
Market marginality as a whole
DiaMedica Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases and neurological disorders. Its success is determined not by the general economic cycles shown in this chart, but by the results of clinical trials. The need for new treatments for chronic diseases creates demand for their developments regardless of the economic situation.
Employees in the company, segment and market as a whole
Number of employees in the company DiaMedica Therapeutics
DiaMedica Therapeutics is a clinical-stage biotech company focused on treating kidney diseases and neurological disorders. This graph shows a small but highly qualified team. The size of the team reflects the current stage of development. A significant increase would signal progression to late-stage trials.
Share of the company's employees DiaMedica Therapeutics within the market segment - Pharma kidney
DiaMedica Therapeutics is a clinical-stage biotech focused on treating kidney disease and stroke. Its team is comprised of a small but highly effective group of scientists. This chart clearly demonstrates the pattern of such companies: a minimal share of employees in the sector does not indicate weakness, but rather a focus on research, where value is created through discovery.
Number of employees in the market segment - Pharma kidney
DiaMedica Therapeutics is a biotechnology company focused on developing drugs for the treatment of kidney diseases and neurological disorders. This schedule reflects the long and risky path of clinical research. The growth or stability of the scientific and clinical staff directly depends on the results of trials and the company's ability to attract funding for further development.
Number of employees in the market as a whole
DiaMedica Therapeutics is a biopharmaceutical company focused on treating kidney diseases and neurological disorders. Its staff consists of scientists and researchers, whose hiring depends on the phases of clinical trials and funding. This graph illustrates how this highly specialized scientific field operates independently, often out of phase with general economic cycles.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company DiaMedica Therapeutics (DMAC)
DiaMedica Therapeutics is a biotech company developing drugs to treat kidney disease and stroke. Its entire capital comes from its intellectual property and research team. This chart illustrates the enormous cost per employee, typical for R&D startups, where market valuation is based on the potential of future drugs.
%20of%20the%20company%20DiaMedica%20Therapeutics%20(DMAC)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-DiaMedica-Therapeutics-DMAC&v=1772640437456 "Chart of market capitalization per employee (in thousands of dollars) of the company DiaMedica Therapeutics (DMAC)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma kidney
DiaMedica Therapeutics focuses on developing treatments for kidney diseases and neurological disorders. In biotech, where teams of scientists can spend years working on a single drug, this graph reflects market expectations for their developments. Deviations from the segment average may signal investor confidence in the potential commercial success of their research.
%20by%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-kidney&v=1772640437462 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma kidney")
Market capitalization per employee (in thousands of dollars) for the overall market
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on treating kidney diseases. This metric clearly demonstrates how the market values scientific potential. The company's market capitalization is based on expectations for future drugs, not current revenue, resulting in a very high valuation for each member of its small team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772640437480 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company DiaMedica Therapeutics (DMAC)
DiaMedica is a clinical-stage biotech company focused on treating kidney disease. It's important to understand that they don't yet have any approved products and, therefore, no sales revenue. In their case, this chart doesn't show "profit," but rather the "burn rate" of capital per employee. This is an indicator of the cost of R&D while waiting for a scientific breakthrough.
%20Chart%20DiaMedica%20Therapeutics%20(DMAC)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-DiaMedica-Therapeutics-DMAC&v=1772640437604 "Company Profit Per Employee (in thousands of dollars) Chart DiaMedica Therapeutics (DMAC)")
Profit per employee (in thousands of dollars) in the market segment - Pharma kidney
DiaMedica Therapeutics is a clinical-stage biotech focused on treating kidney disease. The company has no commercial products yet, so its "profit" is a negative number (R&D expenses). This chart illustrates the cost of research per employee, comparing their capital burn rate to the industry standard.
%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-kidney&v=1772640437615 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma kidney")
Profit per employee (in thousands of dollars) for the market as a whole
DiaMedica Therapeutics is a clinical-stage biotech company focused on treating kidney diseases. Currently, the company has virtually no revenue, but it does have a staff of scientists. This metric doesn't reflect profit, but rather the "burn rate" of investment per employee, which is typical in the R&D sector, and reflects the cost of scientific research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772640437630 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee DiaMedica Therapeutics (DMAC)
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on treating kidney diseases and neurological disorders. This chart illustrates the company's status prior to commercialization. Low or nonexistent revenue per employee is typical for a stage when all resources are focused on research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-DiaMedica-Therapeutics-DMAC&v=1772640437646 "Sales chart per company employee DiaMedica Therapeutics (DMAC)")
Sales per employee in the market segment - Pharma kidney
DiaMedica (DMAC) is a clinical-stage biotech focused on treating acute kidney disease and stroke. This chart shows the revenue generated by each employee. It helps understand the company's commercialization stage and how its R&D platform compares to other biotechs operating in this complex niche.
Sales per employee for the market as a whole
DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on treating rare kidney and neurological diseases. Currently, their business is purely R&D. This metric doesn't yet reflect commercial viability, as revenue is almost nonexistent. Future growth will determine whether their DM199 therapy can generate revenue that outpaces staff growth.
Short shares by company, segment and market as a whole
Shares shorted by company DiaMedica Therapeutics (DMAC)
DiaMedica Therapeutics is a clinical-stage biotech focused on treating kidney disease. This chart shows the volume of bearish bets. Bears are betting on a binary risk: if its key drug fails to show convincing results in trials, the stock could collapse, as the company has no other sources of revenue.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-DiaMedica-Therapeutics-DMAC&v=1772640437704 "Short Shares Chart for the Company DiaMedica Therapeutics (DMAC)")
Shares shorted by market segment - Pharma kidney
DiaMedica is a biotech company developing drugs to treat chronic kidney disease and the effects of stroke. It's a risky business. This chart shows bearish bets. "Shorts" here represent investors directly betting that their clinical trials will fail or that their drugs won't receive FDA approval.
Shares shorted by the overall market
DiaMedica Therapeutics (DMAC) is a clinical-stage biotech company targeting kidney disease. (See TVRD.) This is a speculative bet on the success of the trial. This chart shows the overall level of fear. When it rises, investors flee biotechs, especially those working in complex fields with a high failure rate.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator DiaMedica Therapeutics (DMAC)
DiaMedica Therapeutics is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-DiaMedica-Therapeutics-DMAC&v=1772640437751 "RSI 14 indicator chart for the company's stock DiaMedica Therapeutics (DMAC)")
RSI 14 Market Segment - Pharma kidney
DiaMedica (DMAC) is a biotech company focused on treating ischemic stroke and (potentially) kidney disease (CKD). The RSI_14_Seg for "Pharma kidney" (biotech) shows the overall sentiment. The chart helps us understand: is DMAC's volatility a reaction to its trials or is the entire sector overheated?
RSI 14 for the overall market
DiaMedica (DMAC) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DMAC (DiaMedica Therapeutics)
DiaMedica (DMAC) is a biotech company developing drugs to treat chronic kidney disease and ischemic stroke. This chart shows the average 12-month forecast, reflecting analysts' assessments of the likelihood of success in the company's clinical trials in these complex areas.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DMAC-DiaMedica-Therapeutics&v=1772640437863 "A chart showing analyst consensus forecasts for the expected stock price. DMAC (DiaMedica Therapeutics)")
The difference between the consensus estimate and the actual stock price DMAC (DiaMedica Therapeutics)
DiaMedica (DMAC) is a clinical-stage biotech focused on treating acute ischemic stroke and rare kidney diseases. This is an R&D bet. This chart shows the difference between the consensus estimate and the price. It reflects analysts' confidence in the scientific potential of the company's R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DMAC-DiaMedica-Therapeutics&v=1772640437881 "A chart showing the difference between the consensus forecast and the actual stock price. DMAC (DiaMedica Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma kidney
DiaMedica Therapeutics (DMAC) is a biotech company developing a recombinant protein (DM199) for the treatment of acute ischemic stroke and rare kidney diseases. This chart shows overall expectations for the kidney pharmaceutical sector, reflecting whether experts believe in the potential of this therapeutic molecule.
Analysts' consensus forecast for the overall market share price
DiaMedica Therapeutics is a biotech company focused on treating kidney disease and stroke. They are developing a recombinant protein (KLK1) to improve blood flow. This chart shows overall market sentiment. For DiaMedica, as an R&D company, it's important to understand how overall risk appetite (sentiment) influences funding for their clinical trials. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index DiaMedica Therapeutics
DiaMedica is a clinical-stage biotech focused on the treatment of ischemic stroke and, more importantly, chronic kidney disease (CKD). This graph represents pure R&D investment. It likely reflects the market's confidence in their scientific approach (targeting the KLK1 protein) and their progress in clinical trials in these complex areas.
AKIMA Market Segment Index - Pharma kidney
DiaMedica (DMAC) is a clinical-stage biotech focused on kidney disease and stroke; the company is developing its drug (DM199) for the treatment of these common conditions. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D rate (DMAC) differentiate it from the average pharma company?
The AKIM Index for the overall market
DiaMedica Therapeutics is a biopharmaceutical company developing treatments for neurological and renal diseases (ischemic stroke). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this clinical trial, targeting unmet needs, compares to overall economic trends.
